Caspofungin acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314268

CAS#: 179463-17-3 (acetate)

Description: Caspofungin acetate is a lipopeptide antifungal drug. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin acetate for injection was originally approved by FDA in USA, and the EMEA in Europe, in 2001.

Chemical Structure

Caspofungin acetate
CAS# 179463-17-3 (acetate)

Theoretical Analysis

MedKoo Cat#: 314268
Name: Caspofungin acetate
CAS#: 179463-17-3 (acetate)
Chemical Formula: C56H96N10O19
Exact Mass:
Molecular Weight: 1213.42
Elemental Analysis: C, 55.43; H, 7.97; N, 11.54; O, 25.05

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 Same day
50.0mg USD 250.0 Same day
100.0mg USD 450.0 Same day
200.0mg USD 650.0 Same day
500.0mg USD 850.0 Same day
1.0g USD 1250.0 Same day
2.0g USD 1950.0 Same day
5.0g USD 3650.0 Same day
10.0g USD 5950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 162808-62-0 (free base)   179463-17-3 (acetate)    

Synonym: L743872; L-743872; L 743872; MK 0991; MK-0991; MK0991; Caspofungin acetate; brand name: Cancidas.

IUPAC/Chemical Name: (10S,12R)-N-((2R,6S,9S,11S,12S,14aS,15S,20R,23S,25aS)-20-((R)-3-amino-1-hydroxypropyl)-12-((2-aminoethyl)amino)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,15-trihydroxy-6-((R)-1-hydroxyethyl)-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-10,12-dimethyltetradecanamide diacetate


InChi Code: InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30-,33-,34+,35+,36-,37+,38+,40+,41-,42+,43+,44+,45+,46+;;/m1../s1

SMILES Code: CC[C@@H](C)C[C@@H](C)CCCCCCCCC(N[C@@H]1C(N[C@@H]([C@H](O)C)C(N2[C@](C[C@@H](O)C2)([H])C(N[C@@H]([C@H](O)[C@@H](O)C3=CC=C(O)C=C3)C(N[C@H]([C@H](O)CCN)C(N4[C@]([C@@H](O)CC4)([H])C(N[C@H](NCCN)[C@@H](O)C1)=O)=O)=O)=O)=O)=O)=O.CC(O)=O.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1213.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Chen L, Yue Q, Li Y, Niu X, Xiang M, Wang W, Bills GF, Liu X, An Z. Engineering of Glarea lozoyensis for exclusive production of the pneumocandin B0 precursor of the antifungal drug caspofungin acetate. Appl Environ Microbiol. 2015 Mar;81(5):1550-8. doi: 10.1128/AEM.03256-14. Epub 2014 Dec 19. PubMed PMID: 25527531; PubMed Central PMCID: PMC4325176.

2: Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ. Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient. Int J Mol Sci. 2012;13(9):11063-70. doi: 10.3390/ijms130911063. Epub 2012 Sep 6. PubMed PMID: 23109838; PubMed Central PMCID: PMC3472730.

3: Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses. 2008;51 Suppl 1:19-24. doi: 10.1111/j.1439-0507.2008.01524.x. PubMed PMID: 18471157.

4: Chan P, Heatherly K Ms, Kupiec TC Phd, Trissel LA Bs Rph Fashp. Compatibility of Caspofungin Acetate Injection with Other Drugs Simulated Y-Site Coadministration. Int J Pharm Compd. 2008 May-June;12(3):276-278. PubMed PMID: 23969719.

5: Condie CK, Tyler LS, Barker B, Canann DM. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery. Am J Health Syst Pharm. 2008 Mar 1;65(5):454-7. doi: 10.2146/ajhp070322. Erratum in: Am J Health Syst Pharm. 2008 Sep 1;65(17):1597. PubMed PMID: 18281738.

6: Leonard WR Jr, Belyk KM, Conlon DA, Bender DR, DiMichele LM, Liu J, Hughes DL. Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0. J Org Chem. 2007 Mar 30;72(7):2335-43. Epub 2007 Mar 8. PubMed PMID: 17343416.

7: Scotter JM, Chambers ST. Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate. Clin Diagn Lab Immunol. 2005 Nov;12(11):1322-7. PubMed PMID: 16275948; PubMed Central PMCID: PMC1287761.

8: Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005 Feb;49(2):830-2. PubMed PMID: 15673781; PubMed Central PMCID: PMC547325.

9: Grau S, Mateu-De Antonio J. Comment: caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother. 2003 Dec;37(12):1919. PubMed PMID: 14632549.

10: McGee WT, Tereso GJ. Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent. Crit Care Med. 2003 May;31(5):1577-8. PubMed PMID: 12771636.